Skip to main content
. 2023 Nov 20;10:1256997. doi: 10.3389/fvets.2023.1256997

Table 1.

Mannheimia haemolytica isolation and weight of animals at arrival.

Trial TxGroup (n*) Arrival MH culture n (%) MDR MH n (%) Median arrival weight (95% CI) (kg)
Fall 2019 META (41) 10 (24.4)a 0 (0) 228 (215–242)
NO META (41) 2 (4.9)b 0 (0) 230 (219–241)
All (82) 12 (14.6)c 0 (0)e 229 (217–241)
Fall 2020 META (42) 8 (19.0) 3 (7.1) 230 (218–238)
NO META (41) 9 (22.0) 1 (2.4) 230 (218–239)
All (83) 17 (20.5)c 4 (4.8)ef 230 (218–239)
Spring 2021 META (42) 2 (4.8) 0 (0) 232 (219–241)
NO META (40) 5 (12.5) 0 (0) 229 (219–244)
All (82) 7 (8.5)c 0 (0)e 230 (219–242)
Fall 2021 META (42) 19 (45.2) 5 (11.9) 234 (227–249)
NO META (42) 17 (40.5) 8 (19.0) 238 (232–246)
All (84) 36 (42.9)d 13 (15.5)f 237 (229–248)
Overall META (167) 49 (29.3) 8 (4.8) 231 (220–242)
NO META (164) 33 (20.1) 9 (5.5) 233 (220–244)
All (331) 72 (21.8) 17 (5.1) 232 (220–242)

*Group numbers are after removals. Values with different superscripts in the same column of the ‘META’ or ‘NO META’ rows represent a statistical difference between TxGroups within Trial (ab, χ2, p < 0.05). Values with different superscripts in the same column of the ‘All’ rows represent a statistically significant difference among Trials (cd or ef, Pairwise Fisher’s Exact test with Benjamini-Hochberg adjustment, p < 0.05). Percentages represent percent of animals. MH, Mannheimia haemolytica; MDR, multi-drug resistant; SD, standard deviation; META, tulathromycin metaphylaxis; NO META, no tulathromycin metaphylaxis; TxGroup, treatment group.